Merck's Exciting Anti-Virus Pipeline
Merck's got a couple pieces of very promising antiviral news coming down its pipeline. Should investors be getting excited?
The Most (Only) Interesting Comment on Geron's Call
Positive but perplexing data testing imetelstat in myelofibrosis should have Geron's investors excited, and Incyte, Cell Therapeutics, and Gilead Sciences a little worried about their competing drugs.
Will Geron Jump Even More?
Geron shares skyrocket on news from a Mayo Clinic study. Is the stock poised to move even higher now?
Which Big Pharma Is Poised to See Long-Term Gains?
Compared to Bristol-Myers Squibb, Merck has zero growth, a flat stock, and many believe it's only good as a high yield investment. But strong pipeline progress might make it a great under-the-radar buying opportunity.